Science
Novel RNA Aptamer
High target affinity and specificity with short half life
Lead program BB-031:
- First-in-class RNA aptamer
- Rapid-onset, short-acting, reversible thrombolytic drug
- Designed to be safer and more effective than current standard of care, and able to be administered up to 24 hours after stroke onset
Mechanism of Action
Precision-based therapeutic targeting von Willebrand Factor
BB-031 targets von Willebrand Factor (vWF) for the treatment of thrombosis. VWF is an essential structural component of blood clots and a driver of the clotting process. It is present throughout the clot and responsible for its formation, stabilization and expansion.
Studies in multiple small and large animal nonclinical models of ischemic stroke demonstrated the ability of BB-031 to reopen blocked arteries in brain occlusions as late as six hours post-stroke onset.
